Can we not work together to help family practitioners become more effective pain managers?

Jeffrey Fudin; Timothy J Atkinson; Mena Raouf; Michael E Schatman

doi:10.2147/JPR.S121505

Back to Journals » Journal of Pain Research » Volume 9

Editorial

Can we not work together to help family practitioners become more effective pain managers?

Authors Fudin J , Atkinson TJ, Raouf M, Schatman ME

Received 4 September 2016

Accepted for publication 5 September 2016

Published 13 October 2016 Volume 2016:9 Pages 803—806

DOI https://doi.org/10.2147/JPR.S121505

Checked for plagiarism Yes

Editor who approved publication: Prof. Dr. Enrica Santarcangelo

Download Article [PDF]

Jeffrey Fudin,^1,2,3 Timothy J Atkinson,⁴ Mena Raouf,⁴ Michael E Schatman⁵

¹Stratton VA Medical Center, Albany, NY, USA; ²Albany College of Pharmacy and Health Sciences, Albany, NY, USA; ³Scientific and Clinical Affairs, Remitigate LLC, Delmar, NY, USA; ⁴VA Tennessee Valley Healthcare System, Murfreesboro, Nashville, TN, USA; ⁵US Pain Foundation, Bellevue, WA, USA

Snyder et al recently published a review in American Family Physician titled, “Treating Painful Diabetic Peripheral Neuropathy: An Update”, which provided an overview of pharmacologic treatment options for providers; however, some of the recommendations made by the authors were concerning.¹ Recommendations that caught our attention included statements around pregabalin adjustment for renal impairment, using selective serotonin reuptake inhibitors (SSRIs) in the treatment of diabetic peripheral neuropathy (DPN), classification of tramadol, tapentadol, and oxycodone in DPN.

Disclosure

Dr. Fudin disclosed the following: DepoMed (Advisory Board, Speakers Bureau), Endo (Consultant, Speakers Bureau), Kaléo (Speakers Bureau, Advisory Board), Kashiv Pharma (Advisory Board), KemPharm (Consultant), Pernix Therapeutics (Speaker), Remitigate, LLC (Owner), and Scilex Pharmaceuticals (Consultant).

This article is the sole work of the authors, and stated opinions/assertions do not reflect the opinion of employers, employee affiliates, and/or pharmaceutical companies listed. It was not prepared as part of the authors’ duty as federal employees. The authors report no other conflicts of interest in this work.

References

1.		Snyder MJ, Gibbs LM, Lindsay TJ. Treating painful diabetic peripheral neuropathy: an update. Am Fam Physician. 2016;94(3):227–234.
2.		Lyrica^® (pregabalin) [package insert]. New York, NY: Pfizer; 2016.
3.		Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003;43(3):277–283.
4.		Yoo L, Matalon D, Hoffman RS, Goldfarb DS. Treatment of pregabalin toxicity by haemodialysis in a patient with kidney failure. Am J Kidney Dis. 2009;54(6):1127–1130.
5.		Max MB, Lynch SA, Muir K, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326(19):1250–1256.
6.		Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150(3):573–581.
7.		Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. 1990;42(2):135–144.
8.		Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes JT, Gram LF. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther. 1992;52(5):547–552.
9.		Otto M, Bach FW, Jensen TS, Brosen K, Sindrup SH. Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial. Pain. 2008;139(2):275–283.
10.		Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76(20):1758–1765.
11.		Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–2293.
12.		International Association for the Study of Pain. Pharmacological management of neuropathic pain. Pain. 2010;18(9):1–7.
13.		Raffa RB, Buschmann H, Christoph T, et al. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother. 2012;13(10):1437–1449.
14.		Codd E, Shank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting activity of central acting analgesics. J Pharmacol Exp Ther. 1995;274(3):1263–1270.
15.		Hartrick CT, Rozek RJ. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs. 2011;25(5):359–370.
16.		Nucynta^® (tapentadol immediate release oral tablets) package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2013.
17.		Zorn KE, Fudin J. Treatment of neuropathic pain: the role of unique opioid agents. Pract Pain Manag. 2011;11(4):26–33.
18.		Pham T, Fudin J, Raffa R. Is levorphanol a better opioid than methadone. Pain Med. 2015;16(9):1673–1679.
19.		Gaskell H, Moore RA, Derry S, Stannard C. Oxycodone for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;(6):CD010692.
20.		Breuer B, Cruciani R, Portenoy RK. Pain management by primary care physicians, pain physicians, chiropractors, and acupuncturists: a national survey. South Med J. 2010;103(8):738–747.
21.		Vijayaraghavan M, Penko, J, Guzman D, Miaskowski C, Kushel MB. Primary care providers’ view on chronic pain management among high-risk patients in safety net settings. Pain Med. 2012;13(9):1141–1148.
22.		Gatchel RJ, McGeary DD, McGeary CA, Lippe B. Interdisciplinary chronic pain management: past, present, and future. Am Psychol. 2014;69(2):119–130.
23.		Roy A, Breton M, Loslier J. Providing continuity of care to a specific population: attracting new family physicians. Can Fam Physician. 2016;62(5):e256–e262.
		Dove Medical Press encourages responsible, free and frank academic debate. The content of the Journal of Pain Research ‘Editorial’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Journal of Pain Research editors. While all reasonable steps have been taken to confirm the content of each Editorial, Dove Medical Press accepts no liability in respect of the content of any Editorial, nor is it responsible for the content and accuracy of any Editorial.

Creative Commons License © 2016 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]